Next Generation Therapeutic Classes

Using proprietary SOLVE™ (Selective Oncolytic Vaccinia Engineering) platform, Jennerex is constructing novel oncolytic viruses that have unique features and are targeted for particular cancer types. The SOLVE platform allows us to select the optimal strain and species of virus for the backbone, enhancing the selectivity and potency through multiple targeted mutations, and creating enhancements through the addition of relevant transgenes.